Compare
Regen BioPharma Inc vs Abvc Biopharma, Inc. vs Vyome Holdings, Inc vs Lisata Therapeutics, Inc.
| Latest fiscal year | Regen BioPharma Inc RGBP | Abvc Biopharma, Inc. ABVC | Vyome Holdings, Inc HIND | Lisata Therapeutics, Inc. LSTA |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $236.6K | $296.0K | $319.7K | $170.0K |
| Revenue growth (YoY) | 0.0% | -41.9% | +24.4% | -83.0% |
| Gross margin | n/a | n/a | 68.4% | n/a |
| Operating margin | -143.1% | n/m | n/m | n/m |
| Net margin | -538.8% | n/m | n/m | n/m |
| Net income | -$1.27M | -$7.91M | -$10.26M | -$16.59M |
| EPS (Diluted) | -$0.05 | -$0.39 | -$4.86 | -$1.91 |
| Operating cash flow | -$383.6K | -$2.99M | -$3.75M | -$15.95M |
| Free cash flow | n/a | n/a | n/a | -$15.98M |
| Cash & equivalents | $69.6K | $681.5K | $4.98M | $15.96M |
| Total assets | $274.6K | $21.06M | $6.50M | $17.74M |
| Total liabilities | $6.56M | $7.76M | $2.74M | $3.14M |
| Shareholders' equity | -$6.28M | $11.11M | $3.76M | $14.86M |
| Return on year-end equity | n/a | -71.2% | -272.8% | -111.7% |
| Shares outstanding | 39.37M | 25.05M | 5.92M | 8.83M |
Revenue, most recent five fiscal years
| Fiscal year | Regen BioPharma Inc | Abvc Biopharma, Inc. | Vyome Holdings, Inc | Lisata Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $236.6K Ended 2025-09-30 | $296.0K Ended 2025-12-31 | $319.7K Ended 2025-12-31 | $170.0K Ended 2025-12-31 |
| 1 year earlier | $236.6K Ended 2024-09-30 | $509.6K Ended 2024-12-31 | $256.9K Ended 2024-12-31 | $1.00M Ended 2024-12-31 |
| 2 years earlier | $236.6K Ended 2023-09-30 | n/a | $8.68M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $11.24M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $13.60M Ended 2021-12-31 | n/a |